Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy

Trial Profile

A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs AMG 592 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 13 Feb 2019 Planned End Date changed from 29 Jun 2021 to 17 Aug 2021.
    • 13 Feb 2019 Planned primary completion date changed from 22 Sep 2020 to 10 Nov 2020.
    • 09 Jan 2019 Planned End Date changed from 18 Oct 2020 to 29 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top